Key result
New oral anticoagulants like dabigatran and rivaroxaban appear as safe and effective as warfarin during atrial fibrillation ablation, though current studies are underpowered to detect small differences.
Why the study?
Do new oral anticoagulants (NOACs) provide comparable safety and efficacy to warfarin in patients undergoing catheter ablation for atrial fibrillation?
Do new oral anticoagulants (NOACs) provide comparable safety and efficacy to warfarin in patients undergoing catheter ablation for atrial fibrillation?
This review suggests dabigatran and rivaroxaban are reasonable periprocedural alternatives to warfarin during AF ablation, though larger standardized trials are needed to definitively confirm safety and efficacy.
May support NOACs as warfarin alternatives in AF ablation; leaves open confirmation of equivalence in larger powered trials.
No takes yet. Share an insight, caveat, or question.
Zak et al. (2015) conducted a review in Atrial fibrillation undergoing catheter ablation. New oral anticoagulants (dabigatran, rivaroxaban) vs. Warfarin was evaluated on Thromboembolic and bleeding complications. New oral anticoagulants like dabigatran and rivaroxaban appear as safe and effective as warfarin during atrial fibrillation ablation, though current studies are underpowered to detect small differences.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: